GLA and Fabry disease: For the treatment of Fabry disease, this risk has been eluded using a protocol based on discontinuous, every other day administration (Germain et al, 2016), taking advantage of the short half‐life of the drug compared with that of alpha‐galactosidase A. New, allosteric drugs that interact with non‐catalytic domains of the enzyme and are thus non‐inhibitory may represent an alternative strategy to minimize the risk of unwanted enzyme inhibition (Porto et al, 2012; Parenti et al, 2015a).